PANCREATIC NEUROENDOCRINE TUMORS: CLINICOPATHOLOGICAL ANALYSIS AND POSTOPERATIVE SURVIVAL FOLLOWING SURGICAL RESECTION-A DECADE OF EXPERIENCE AT A TERTIARY UNIVERSITY HOSPITAL
Authors:
- Mariana Martins Sanches FerreiraMFMariana Martins Sanches Ferreira
- Philipe Franco Do Amaral TafnerPTPhilipe Franco Do Amaral Tafner
- Martinho Antonio GesticMGMartinho Antonio Gestic
- Murillo Pimentel UtriniMUMurillo Pimentel Utrini
- Francisco Callejas-NetoFCFrancisco Callejas-Neto
- Everton CazzoECEverton Cazzo
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 63
Abstract
Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms of the digestive system, with variable prognoses and biological behaviors. Surgical resection remains the mainstay of treatment. Objective: To evaluate the clinicopathological characteristics and surgical outcomes of patients with PNETs who underwent resection at the Hospital de Clínicas, UNICAMP. Methods: This is a retrospective cohort study including 24 patients who underwent surgical resection between 2013 and 2023. Clinical, demographic, histopathological, and survival data were analyzed. The primary outcome was overall survival. Results: The mean age was 53.9 ± 14.4 years, with a predominance of female patients (66.7%). Most tumors were nonfunctioning (79.1%), with abdominal pain (79.2%) and weight loss (50%) being the most common symptoms. The surgical procedures performed were distal pancreatectomy (54.2%), pancreaticoduodenectomy (41.6%), and enucleation (4.2%). Histological classification revealed 62.5% grade 2 tumors, 33.3% grade 1, and 4.2% MiNEN. Mean overall survival was 70.4 ± 58 months. There was a trend toward longer survival in grade 1 tumors (98 ± 68.1 months) compared to grade 2 (59.1 ± 49.5 months; P=0.06). Postoperative mortality was 8.3%, associated with pancreaticoduodenectomy. Conclusion: Histological grading remains a key prognostic factor in PNETs. Surgical resection remains the cornerstone of treatment. Multicenter studies are necessary to validate these findings on a larger scale.Keywords
This publication has 7 references indexed in Scilit:
- The Treatment of Pancreatic Neuroendocrine Tumors - A Retrospective Single-Centre StudyChirurgia, 2025
- Advances in Management of Nonfunctional Pancreas Neuroendocrine TumorsSurgical Clinics of North America, 2024
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialThe Lancet Oncology, 2021
- Surgical Management of Neuroendocrine Tumours of the PancreasJournal of Clinical Medicine, 2020
- Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and managementWorld Journal of Gastroenterology, 2020
- Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter studySurgery, 2016
- NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine TumorPancreas, 2010